Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C. WASHINGTON, Aug. 26, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET. The event will be hosted by Julie Sawyer Montgomery,... Read more
Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics. Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together... Read more
myeloMATCH Precision Medicine Clinical Trial Leverages Next-Day Genomic Testing to Quickly Match Patients with Appropriate Trials Across North America WALTHAM, Mass.–(BUSINESS WIRE)– To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is partnering with the National... Read more
Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics WASHINGTON, June 19, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (“Danaher” or the “Company”), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr.... Read more
Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research The Thermo Scientific™ Stellar™ mass spectrometer combines speed and sensitivity to advance precision medicine ANAHEIM, Calif.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast... Read more
ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITech offers the proprietary, fully automated sample-to-answer (S2A) systems InGenius® and BeGenius® for molecular testing in mid-sized hospitals Diversified ELITech MDx assay portfolio focused on esoteric infectious disease testing ELITech has its R&D,... Read more
New MBT Pathfinder® IVD robot for automated MALDI Biotyper® target preparation New LiquidArray® MTB-XDR panel for simultaneous detection of M. tuberculosis complex bacteria, and their resistances to five WHO-recommended second-line drugs against multidrug-resistant tuberculosis Pending ELITech acquisition has received all regulatory clearances; closing now expected in the second quarter of 2024 BARCELONA, Spain–(BUSINESS WIRE)– At... Read more
ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral... Read more
Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems Acquisition Complements Bruker’s Preclinical Imaging Portfolio with In-Vivo Optical Imaging TUCSON, Ariz.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced that it has acquired Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems. This acquisition fills a gap in... Read more
Danaher Launches Collaboration with Cincinnati Children’s Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development,... Read more